%0 Journal Article
%T A systematic review of 4D magnetic resonance imaging techniques for abdominal radiotherapy treatment planning.
%A Aljaafari L
%A Bird D
%A Buckley DL
%A Al-Qaisieh B
%A Speight R
%J Phys Imaging Radiat Oncol
%V 31
%N 0
%D 2024 Jul
%M 39071158
暂无%R 10.1016/j.phro.2024.100604
%X UNASSIGNED: Four-dimensional magnetic resonance imaging (4DMRI) has gained interest as an alternative to the current standard for motion management four-dimensional tomography (4DCT) in abdominal radiotherapy treatment planning (RTP). This review aims to assess the 4DMRI literature in abdomen, focusing on technical considerations and the validity of using 4DMRI for patients within radiotherapy protocols.
UNASSIGNED: The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive search was performed across the Medline, Embase, Scopus, and Web of Science databases, covering all years up to December 31, 2023. The studies were grouped into two categories: 4DMRI reconstructed from 3DMRI acquisition; and 4DMRI reconstructed from multi-slice 2DMRI acquisition.
UNASSIGNED: A total of 39 studies met the inclusion criteria and were analysed to provide key findings. Key findings were 4DMRI had the potential to improve abdominal RTP for patients by providing accurate tumour definition and motion assessment compared to 4DCT. 4DMRI reconstructed from 3DMRI acquisition showed promise as a feasible approach for motion management in abdominal RTP regarding spatial resolution. Currently,the slice thickness achieved on 4DMRI reconstructed from multi-slice 2DMRI acquisitions was unsuitable for clinical purposes. Lastly, the current barriers for clinical implementation of 4DMRI were the limited availability of validated commercial solutions and the lack of larger cohort comparative studies to 4DCT for target delineation and plan optimisation.
UNASSIGNED: 4DMRI showed potential improvements in abdominal RTP, but standards and guidelines for the use of 4DMRI in radiotherapy were required to demonstrate clinical benefits.